# Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease

> **NCT00294112** · PHASE2 · COMPLETED · sponsor: **Mesoblast, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Prochymal™ adult human mesenchymal stem cells
- **DRUG:** adult human mesenchymal stem cells

## Key facts

- **NCT ID:** NCT00294112
- **Lead sponsor:** Mesoblast, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03-13
- **Primary completion:** 2006-07-21
- **Final completion:** 2006-07-21
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00294112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00294112, "Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00294112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*